Premium
EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON‐1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC
Author(s) -
Radford J.,
Connors J.M.,
Younes A.,
Gallamini A.,
Ansell S.M.,
Kim W.S.,
Cheong J.,
Flinn I.,
Kalakonda N.,
Kaminski M.,
Pettengell R.,
Onsum M.,
Josephson N.,
Kuroda S.,
Liu R.,
Miao H.,
Gautam A.,
Trepicchio W.L.,
Sureda A.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.99_2630
Subject(s) - medicine , brentuximab vedotin , dacarbazine , oncology , abvd , biomarker , post hoc analysis , progression free survival , gastroenterology , lymphoma , overall survival , cd30 , vincristine , chemotherapy , cyclophosphamide , biochemistry , chemistry